Developer docs
API playgroundTry for free, no card

Search company profiles

Newleos Therapeutics

Full company profile

uuid0000fpm

Namestring
Newleos Therapeutics
Legal namestring
Newleos Therapeutics, Inc.
Websiteurl
newleos.com
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Newleos Therapeutics is a clinical-stage biotechnology company developing oral small molecule therapeutics for neuropsychiatric disorders. Founded in 2024-2025 by Longwood Fund alongside seasoned CNS drug development leaders, the company licensed its entire pipeline of four drug candidates from Roche's neuroscience research team. Newleos targets underserved neuropsychiatric indications including generalized anxiety disorder (GAD), social anxiety disorder (SAD), alcohol use disorder (AUD), and rare neurodevelopmental disorders such as Dup15q syndrome. The pipeline is positioned as first-in-class or best-in-class, with candidates designed to engage validated but previously inaccessible CNS mechanisms (GABAA-γ1, V1a, TAAR1, GABAA-α5) with improved selectivity to reduce side effects relative to current standard of care.

The lead clinical programs include NTX-1472, a highly selective brain-penetrant vasopressin 1a (V1a) receptor antagonist currently in Phase 2 development for SAD; NTX-1955, a GABAA-γ1 positive allosteric modulator designed to avoid the sedation, cognitive impairment, and dependence risks of benzodiazepines in GAD; NTX-2001, a TAAR1 selective partial agonist modulating dopaminergic circuits for AUD; and NTX-1511, a GABAA-α5 negative allosteric modulator for Dup15q syndrome. By early 2026 the company had dosed first participants in the SOAR Phase 2 study of NTX-1472, a U.K. Phase 1b of NTX-1955, and a Phase 1b of NTX-2001, and had secured FDA IND clearance for NTX-1472. NTX-2001 had previously been studied in eight Roche-sponsored trials involving approximately 645 participants, providing a meaningful translational data inheritance.

Newleos is pre-revenue and operates as a venture-backed private biotech headquartered in Boston. The company closed an oversubscribed $93.5 million Series A in February 2025 led by Goldman Sachs Alternatives, with participation from Novo Holdings, Arkin Bio Ventures, DCVC Bio, and Longwood Fund. Patients access the company's investigational products solely through clinical trial participation across the U.S., EU, and U.K.; the company does not offer expanded access. Future revenue is anticipated from commercialization of FDA-approved neuropsychiatric medicines through traditional pharmaceutical distribution channels, though no commercial product is currently approved and no pricing model has been disclosed.

Short descriptiontext

Newleos Therapeutics is a clinical-stage biotechnology company developing oral small molecule therapeutics for neuropsychiatric disorders including GAD, SAD, AUD, and rare neurodevelopmental conditions. Its four-asset pipeline, licensed from Roche, targets GABAA-γ1, V1a, TAAR1, and GABAA-α5 mechanisms with first-in-class or best-in-class potential.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, neuropsychiatric drug development, small molecule therapeutics, anxiety disorder treatments, CNS drug pipeline
Industry4 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Neuropsychiatric Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage company. Future revenue anticipated from commercialization of FDA-approved neuropsychiatric medications. The company is conducting proof-of-concept clinical trials with plans to pursue regulatory approval and commercial launch.

newleos.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Newleos Therapeutics is a clinical-stage biotechnology company developing a pipeline of four oral small molecule drug candidates for neuropsychiatric disorders, all licensed from Roche. The candidates target innovative mechanisms (GABAA-γ1 PAM, V1a antagonist, TAAR1 partial agonist, GABAA-α5 NAM) intended to provide first- or best-in-class treatments for generalized anxiety disorder, social anxiety disorder, alcohol use disorder, and rare neurodevelopmental conditions such as Dup15q syndrome.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • NTX-1955 demonstrated dose-dependent anxiolytic activity matching benzodiazepine efficacy without the side effect profile in preclinical gold-standard anxiety models
+3 more records
Product overview1 text field

Newleos Therapeutics is a clinical-stage biotechnology company developing a pipeline of four oral small molecule drug candidates targeting innovative neuropsychiatric mechanisms of action. The company's clinical-stage pipeline includes: NTX-1955 (GABAA-γ1 PAM for generalized anxiety disorder), NTX-1472 (V1a receptor antagonist for social anxiety disorder), NTX-2001 (TAAR1 partial agonist for alcohol use disorder), and NTX-1511 (GABAA-α5 NAM for Dup15q syndrome). All programs were in-licensed from Roche and offer first- or best-in-class potential with reduced side effects compared to current standard of care.

Product and service4 records
1NTX-1955
CategoryDrug Candidate
Description

A potential first-in-class GABAA-γ1 positive allosteric modulator (PAM) in clinical development for generalized anxiety disorder (GAD). Designed to selectively engage GABAergic transmission in the amygdala to avoid sedation, cognitive impairment, and dependence risks associated with benzodiazepines.

2NTX-1472
CategoryDrug Candidate
Description

A potential best-in-class, highly selective, brain-penetrant vasopressin 1a (V1a) receptor antagonist in Phase 2 development for social anxiety disorder (SAD). Targets brain regions essential for social and threat processing.

3NTX-2001
CategoryDrug Candidate
Description

A selective partial agonist of trace amine-associated receptor 1 (TAAR1) in Phase 1b development for alcohol use disorder (AUD). Modulates dopaminergic neurotransmission in addiction circuits to reduce alcohol cravings and consumption.

4NTX-1511
CategoryDrug Candidate
Description

A selective negative allosteric modulator (NAM) of the GABAA-α5 subunit in clinical development for Dup15q syndrome, a rare neurodevelopmental disorder. Designed to reduce functional consequences of GABAA receptor gene duplication.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or Integration
Description

Licensed the entire clinical-stage pipeline from Roche, including programs targeting GABAA-γ1 (NTX-1955), V1a (NTX-1472), TAAR1 (NTX-2001), and GABAA-α5 (NTX-1511). These were originally discovered by Roche's neuroscience research team.

Strategic tierCoreTypeOthers
Description

Filed clinical trial applications with EU health authorities for two Phase 1b studies of NTX-1955 in generalized anxiety disorder. Dosing commenced for one study with EU health authority approval.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CNS-focused biotech developing therapies for schizophrenia, epilepsy, and Parkinson's disease, acquired by AbbVie for $8.7B. Highly comparable clinical-stage neuroscience pipeline with similar BD exit precedent.

TypeDirect peer
Description

Commercial-stage CNS biopharma with Auvelity (dextromethorphan-bupropion) for major depressive disorder and other neuropsychiatric programs. Direct peer in CNS specialty pharma targeting psychiatric indications.

TypeDirect peer
Description

CNS-focused biopharma developing Zurzuvae (zuranolone) for postpartum depression and other neuropsychiatric indications. Comparable as a clinical-stage neurology specialty pharma with overlapping leadership talent (Tammy Phinney, Tiffany Lago came from Sage) and similar regulatory and clinical playbook.

TypeDirect peer
Description

Developed KarXT (xanomeline-trospium / Cobenfy) for schizophrenia and was acquired by Bristol Myers Squibb for $14B. Closest direct peer: clinical-stage CNS biotech with novel-mechanism psychiatry assets that achieved a major BD exit.

TypeDirect peer
Description

Clinical-stage biotech developing precision medicines for CNS disorders including epilepsy and essential tremor. Closely comparable as a Boston-area, CNS-focused, clinical-stage biotech with similar headcount and funding profile.

TypeDirect peer
Description

Clinical-stage neuropsychiatry biotech using AI-enabled biomarkers to develop precision depression and anxiety treatments. Comparable stage, mechanism-novelty, and indication overlap with Newleos's anxiety programs.

TypeDirect peer
Description

Clinical-stage neuropsychiatric biotech developing novel therapies for depression, schizophrenia, and other brain disorders with a multi-program platform approach. Comparable clinical-stage CNS portfolio model and BD exit potential.

TypeDirect peer
Description

Clinical-stage neuroscience company developing therapies for schizophrenia and other CNS disorders using novel mechanisms. Comparable as a clinical-stage CNS biotech with novel-mechanism candidates and similar funding trajectory.

TypeEmerging player
Description

Clinical-stage neuroscience company developing precision medicines for epilepsy and focal onset seizures. Comparable stage and CNS focus, with overlapping clinical operations and translational neuroscience expertise.

TypeEmerging player
Description

Clinical-stage neuropsychiatry company developing psychedelic-based therapies for depression and AUD. Adjacent peer sharing neuropsychiatric focus and clinical-stage AUD program (NTX-2001 comparable to Cybin's lead candidates); also shares Marcelo Gutiérrez as former VP Clinical Pharmacology.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Newleos Therapeutics

Neuropsychiatric Pharmaceuticalsnewleos.com

Newleos Therapeutics is a clinical-stage biotechnology company developing oral small molecule therapeutics for neuropsychiatric disorders including GAD, SAD, AUD, and rare neurodevelopmental conditions. Its four-asset pipeline, licensed from Roche, targets GABAA-γ1, V1a, TAAR1, and GABAA-α5 mechanisms with first-in-class or best-in-class potential.

What Newleos Therapeutics does

Newleos Therapeutics is a clinical-stage biotechnology company developing oral small molecule therapeutics for neuropsychiatric disorders. Founded in 2024-2025 by Longwood Fund alongside seasoned CNS drug development leaders, the company licensed its entire pipeline of four drug candidates from Roche's neuroscience research team. Newleos targets underserved neuropsychiatric indications including generalized anxiety disorder (GAD), social anxiety disorder (SAD), alcohol use disorder (AUD), and rare neurodevelopmental disorders such as Dup15q syndrome. The pipeline is positioned as first-in-class or best-in-class, with candidates designed to engage validated but previously inaccessible CNS mechanisms (GABAA-γ1, V1a, TAAR1, GABAA-α5) with improved selectivity to reduce side effects relative to current standard of care.

The lead clinical programs include NTX-1472, a highly selective brain-penetrant vasopressin 1a (V1a) receptor antagonist currently in Phase 2 development for SAD; NTX-1955, a GABAA-γ1 positive allosteric modulator designed to avoid the sedation, cognitive impairment, and dependence risks of benzodiazepines in GAD; NTX-2001, a TAAR1 selective partial agonist modulating dopaminergic circuits for AUD; and NTX-1511, a GABAA-α5 negative allosteric modulator for Dup15q syndrome. By early 2026 the company had dosed first participants in the SOAR Phase 2 study of NTX-1472, a U.K. Phase 1b of NTX-1955, and a Phase 1b of NTX-2001, and had secured FDA IND clearance for NTX-1472. NTX-2001 had previously been studied in eight Roche-sponsored trials involving approximately 645 participants, providing a meaningful translational data inheritance.

Newleos is pre-revenue and operates as a venture-backed private biotech headquartered in Boston. The company closed an oversubscribed $93.5 million Series A in February 2025 led by Goldman Sachs Alternatives, with participation from Novo Holdings, Arkin Bio Ventures, DCVC Bio, and Longwood Fund. Patients access the company's investigational products solely through clinical trial participation across the U.S., EU, and U.K.; the company does not offer expanded access. Future revenue is anticipated from commercialization of FDA-approved neuropsychiatric medicines through traditional pharmaceutical distribution channels, though no commercial product is currently approved and no pricing model has been disclosed.

Newleos Therapeutics firmographics

Firmographics
Name
Newleos Therapeutics
Legal name
Newleos Therapeutics, Inc.
Website
https://newleos.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Short description
Newleos Therapeutics is a clinical-stage biotechnology company developing oral small molecule therapeutics for neuropsychiatric disorders including GAD, SAD, AUD, and rare neurodevelopmental conditions. Its four-asset pipeline, licensed from Roche, targets GABAA-γ1, V1a, TAAR1, and GABAA-α5 mechanisms with first-in-class or best-in-class potential.
Ownership category
akta.pro rank

Newleos Therapeutics industry classification

Industry
Product category
Neuropsychiatric Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Clinical-stage biotechnology
  • Neuropsychiatric drug development
  • Small molecule therapeutics
  • Anxiety disorder treatments
  • CNS drug pipeline

Where Newleos Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Newleos Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Future revenue anticipated from commercialization of FDA-approved neuropsychiatric medications. The company is conducting proof-of-concept clinical trials with plans to pursue regulatory approval and commercial launch.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Newleos Therapeutics product offering

Product offering

Core offering

Newleos Therapeutics is a clinical-stage biotechnology company developing a pipeline of four oral small molecule drug candidates for neuropsychiatric disorders, all licensed from Roche. The candidates target innovative mechanisms (GABAA-γ1 PAM, V1a antagonist, TAAR1 partial agonist, GABAA-α5 NAM) intended to provide first- or best-in-class treatments for generalized anxiety disorder, social anxiety disorder, alcohol use disorder, and rare neurodevelopmental conditions such as Dup15q syndrome.

Product overview

Newleos Therapeutics is a clinical-stage biotechnology company developing a pipeline of four oral small molecule drug candidates targeting innovative neuropsychiatric mechanisms of action. The company's clinical-stage pipeline includes: NTX-1955 (GABAA-γ1 PAM for generalized anxiety disorder), NTX-1472 (V1a receptor antagonist for social anxiety disorder), NTX-2001 (TAAR1 partial agonist for alcohol use disorder), and NTX-1511 (GABAA-α5 NAM for Dup15q syndrome). All programs were in-licensed from Roche and offer first- or best-in-class potential with reduced side effects compared to current standard of care.

Differentiator

Problem solved

Functional benefit

Products and services

  • NTX-1955 A potential first-in-class GABAA-γ1 positive allosteric modulator (PAM) in clinical development for generalized anxiety disorder (GAD). Designed to selectively engage GABAergic transmission in the amygdala to avoid sedation, cognitive impairment, and dependence risks associated with benzodiazepines.
  • NTX-1472 A potential best-in-class, highly selective, brain-penetrant vasopressin 1a (V1a) receptor antagonist in Phase 2 development for social anxiety disorder (SAD). Targets brain regions essential for social and threat processing.
  • NTX-2001 A selective partial agonist of trace amine-associated receptor 1 (TAAR1) in Phase 1b development for alcohol use disorder (AUD). Modulates dopaminergic neurotransmission in addiction circuits to reduce alcohol cravings and consumption.
  • NTX-1511 A selective negative allosteric modulator (NAM) of the GABAA-α5 subunit in clinical development for Dup15q syndrome, a rare neurodevelopmental disorder. Designed to reduce functional consequences of GABAA receptor gene duplication.

Quantifiable outcome

  • NTX-1955 demonstrated dose-dependent anxiolytic activity matching benzodiazepine efficacy without the side effect profile in preclinical gold-standard anxiety models
  • +3 more outcomes

Companies that use Newleos Therapeutics

Customer profile

Segments4 records

Ideal customer profiles1 record

Newleos Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Newleos Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • RochecoreTechnology or IntegrationLicensed the entire clinical-stage pipeline from Roche, including programs targeting GABAA-γ1 (NTX-1955), V1a (NTX-1472), TAAR1 (NTX-2001), and GABAA-α5 (NTX-1511). These were originally discovered by Roche's neuroscience research team.
  • European Union Health AuthoritiescoreOthersFiled clinical trial applications with EU health authorities for two Phase 1b studies of NTX-1955 in generalized anxiety disorder. Dosing commenced for one study with EU health authority approval.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Newleos Therapeutics competitors and assessment

Company assessment

Direct peers

  • Cerevel Therapeutics: CNS-focused biotech developing therapies for schizophrenia, epilepsy, and Parkinson's disease, acquired by AbbVie for $8.7B. Highly comparable clinical-stage neuroscience pipeline with similar BD exit precedent.
  • Axsome Therapeutics: Commercial-stage CNS biopharma with Auvelity (dextromethorphan-bupropion) for major depressive disorder and other neuropsychiatric programs. Direct peer in CNS specialty pharma targeting psychiatric indications.
  • Sage Therapeutics: CNS-focused biopharma developing Zurzuvae (zuranolone) for postpartum depression and other neuropsychiatric indications. Comparable as a clinical-stage neurology specialty pharma with overlapping leadership talent (Tammy Phinney, Tiffany Lago came from Sage) and similar regulatory and clinical playbook.
  • Karuna Therapeutics: Developed KarXT (xanomeline-trospium / Cobenfy) for schizophrenia and was acquired by Bristol Myers Squibb for $14B. Closest direct peer: clinical-stage CNS biotech with novel-mechanism psychiatry assets that achieved a major BD exit.
  • Praxis Precision Medicines: Clinical-stage biotech developing precision medicines for CNS disorders including epilepsy and essential tremor. Closely comparable as a Boston-area, CNS-focused, clinical-stage biotech with similar headcount and funding profile.
  • Alto Neuroscience: Clinical-stage neuropsychiatry biotech using AI-enabled biomarkers to develop precision depression and anxiety treatments. Comparable stage, mechanism-novelty, and indication overlap with Newleos's anxiety programs.
  • Neumora Therapeutics: Clinical-stage neuropsychiatric biotech developing novel therapies for depression, schizophrenia, and other brain disorders with a multi-program platform approach. Comparable clinical-stage CNS portfolio model and BD exit potential.
  • MapLight Therapeutics: Clinical-stage neuroscience company developing therapies for schizophrenia and other CNS disorders using novel mechanisms. Comparable as a clinical-stage CNS biotech with novel-mechanism candidates and similar funding trajectory.

Emerging players

  • Rapport Therapeutics: Clinical-stage neuroscience company developing precision medicines for epilepsy and focal onset seizures. Comparable stage and CNS focus, with overlapping clinical operations and translational neuroscience expertise.
  • Cybin: Clinical-stage neuropsychiatry company developing psychedelic-based therapies for depression and AUD. Adjacent peer sharing neuropsychiatric focus and clinical-stage AUD program (NTX-2001 comparable to Cybin's lead candidates); also shares Marcelo Gutiérrez as former VP Clinical Pharmacology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Newleos Therapeutics social profiles

Digital presence

Newleos Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Newleos Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Newleos Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Newleos Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Newleos Therapeutics

What does Newleos Therapeutics do?

Newleos Therapeutics is a clinical-stage biotechnology company developing a pipeline of four oral small molecule drug candidates for neuropsychiatric disorders, all licensed from Roche. The candidates target innovative mechanisms (GABAA-γ1 PAM, V1a antagonist, TAAR1 partial agonist, GABAA-α5 NAM) intended to provide first- or best-in-class treatments for generalized anxiety disorder, social anxiety disorder, alcohol use disorder, and rare neurodevelopmental conditions such as Dup15q syndrome.

Is Newleos Therapeutics a public or private company?

Newleos Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Newleos Therapeutics founded?

Newleos Therapeutics was founded in 2025. It employs 11 to 50 people.

Where is Newleos Therapeutics based?

Newleos Therapeutics is headquartered in Boston, United States, in the North America region.

How does Newleos Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Newleos Therapeutics's main competitors?

Direct peers on record are Cerevel Therapeutics, Axsome Therapeutics, Sage Therapeutics, Karuna Therapeutics, Praxis Precision Medicines, Alto Neuroscience, Neumora Therapeutics and MapLight Therapeutics. Emerging players are Rapport Therapeutics and Cybin.

Does Newleos Therapeutics have an API?

No public API is recorded for Newleos Therapeutics.

What industry is Newleos Therapeutics in?

Newleos Therapeutics's product category is Neuropsychiatric Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Newleos Therapeutics Receives Up To $15.5 Million NIH Grant And FDA Fast Track Designation For NTX-2001Newleos Therapeutics received a five-year NIDA grant of up to $15.5 million and FDA Fast Track designation for its investigational drug NTX-2001. The grant will fund Phase 1 and Phase 2 studies for cocaine use disorder, while Fast Track supports the alcohol use disorder program. Topline results from the Phase 1b study are expected in the first half of 2027.The Pharma LetterNewleos TherapeuticsNewleos Therapeutics, a Boston-based clinical-stage neuroscience company, secured $93.5 million in an oversubscribed Series A financing round in February 2025 to advance its proof-of-concept clinical trials. Led by Goldman Sachs Alternatives, the financing also included participation from Novo Holdings A/S, Longwood Fund, DCVC Bio, and Arkin Bio Capital. The funds will further develop treatments for various neuropsychiatric disorders, focusing on novel mechanisms with a lead program targeting anxiety disorders.FinancialContent Business PageNewleos Names Rohan Palekar as Board ChairmanNewleos Therapeutics appointed Rohan Palekar, former CEO of 89bio, as Chairman of its Board of Directors, with Christoph Westphal stepping down from the Executive Chairman role but remaining on the board. Palekar led 89bio from inception through Phase 3 development before the company was acquired by Roche for up to $3.5 billion in 2025. He brings over 30 years of biotech industry experience to guide Newleos through key clinical inflection points in its ongoing anxiety trials.Stock TitanNewleos Names Former 89bio CEO Board ChairmanNewleos Therapeutics announced the appointment of Rohan Palekar, former CEO of 89bio, as Chairman of its Board of Directors, with founding Executive Chairman Christoph Westphal stepping down from that role while remaining on the board. Palekar brings over 30 years of industry experience, having previously led 89bio through Phase 3 development before its acquisition by Roche for up to $3.5 billion in 2025. The appointment is aimed at supporting Newleos as it approaches key clinical inflection points in its ongoing anxiety trials.Clinical Trials ArenaFirst patient dosed in Newleos’ Phase Ib trial of NTX-2001Newleos Therapeutics has commenced a Phase Ib trial for NTX-2001, a medication aimed at treating alcohol use disorder (AUD), marking the first evaluation of a TAAR1 partial agonist in clinical settings for this condition. The trial, conducted in collaboration with Yale School of Medicine, will examine NTX-2001's effects on alcohol consumption, cravings, and safety among participants diagnosed with AUD. This study is significant as it represents a potential advancement in addiction medicine, especially for disorders involving dopamine dysregulation.BioSpaceNewleos Announces Dosing of First Participant in Phase 1b Study of NTX-2001 for Alcohol Use DisorderNewleos Therapeutics announced the first participant has been dosed in its Phase 1b study of NTX-2001, a TAAR1 partial agonist for alcohol use disorder. The randomized, double-blind, placebo-controlled trial, conducted with Yale School of Medicine, will measure reductions in alcohol consumption and cravings. The study is actively enrolling participants ages 21 to 60.Business Wire BlogNewleos Announces Dosing of First Participant in Phase 1b Study of NTX-2001 for Alcohol Use DisorderNewleos Therapeutics announced the first participant has been dosed in its Phase 1b study of NTX-2001, a TAAR1 partial agonist for alcohol use disorder. The randomized, double-blind, placebo-controlled trial, conducted with Yale School of Medicine, will measure reductions in alcohol consumption and cravings. The study is actively enrolling participants ages 21 to 60.BioSpaceNewleos Announces Dosing of First Participant in U.K. Phase 1b Study of NTX-1955 in Generalized Anxiety DisorderNewleos Therapeutics, Inc. has announced the dosing of the first participant in its Phase 1b study of NTX-1955 for generalized anxiety disorder, which is being conducted in the U.K. This study aims to evaluate the safety and tolerability of NTX-1955, a potential first-in-class treatment, and follows two other Phase 1b trials in the EU. Data from these studies are expected to inform the design of a subsequent Phase 2 efficacy study.PharmiWeb.comNewleos Announces Dosing of First Participant in U.K. Phase 1b Study of NTX-1955 in Generalized Anxiety DisorderNewleos Therapeutics announced the dosing of the first participant in its U.K. Phase 1b study of NTX-1955, a GABA A-γ1 positive allosteric modulator being evaluated for generalized anxiety disorder. The multi-center, randomized, double-blind, placebo-controlled trial will enroll adults aged 18-55 with GAD and assess safety and tolerability over a six-week period with once-daily dosing. Data from this U.K. study, along with two other Phase 1b trials already underway in the EU, are expected to inform dose selection and design for a subsequent Phase 2 efficacy study.BioSpaceNewleos Therapeutics Announces Dosing of First Participant in SOAR Phase 2 Study of NTX-1472 for Social Anxiety DisorderNewleos Therapeutics, Inc. announced that the first participant has been dosed in the Phase 2 study of NTX-1472 for social anxiety disorder. This randomized, double-blind, placebo-controlled multi-center study aims to evaluate the safety, tolerability, and efficacy of NTX-1472 in adults with this disorder. The event underscores Newleos' progress in developing innovative treatments for neuropsychiatric disorders, a field with significant unmet medical needs.